Simon Bodek

Simon Bodek

Auto-generated profile, based on publicly available information

Simon Bodek

Department of Medicine, University of Melbourne, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
AMAmali Mallawaarachchi
Amali Mallawaarachchi
LFLindsay Fowles
Lindsay Fowles
LWLouise Wardrop
Louise Wardrop
AWAlasdair Wood
Alasdair Wood
RORosie O'SHea
Rosie O'SHea
Andrew MallettAndrew Mallett
Andrew Mallett
Key Points: Twenty-five percent of those with unexplained kidney failure have a monogenic cause. Whole genome sequencing with broad gene panel analysis is a feasible diagnostic approach in nephrology. Background: The cause of kidney failure is unknown in approximately 10% of patients with stage 5 chronic kidney disease (CKD). For those who first present to nephrology care with kidney failure, standard investigations of serology, imaging, urinalysis, and kidney biopsy are limited differentiators of etiology. We aimed to determine the diagnostic utility of whole genome sequencing (WGS) with analysis of a broad kidney gene panel in patients with kidney failure of unknown cause. Methods: We prospectively recruited 100 participants who reached CKD stage 5 at the age of ≤50 years and had an unknown cause of kidney failure after standard investigation. Clinically accredited WGS was performed in this national cohort after genetic counseling. The primary analysis was targeted to 388 kidney-related genes with second-tier, genome-wide, and mitochondrial analysis. Results: The cohort was 61% male and the average age of participants at stage 5 CKD was 32 years (9 months to 50 years). A genetic diagnosis was made in 25% of participants. Disease-causing variants were identified across autosomal dominant tubulointerstitial kidney disease (6), glomerular disorders (4), ciliopathies (3), tubular disorders (2), Alport syndrome (4), and mitochondrial disease (1). Most diagnoses (80%) were in autosomal dominant, X-linked, or mitochondrial conditions (UMOD; COL4A5; INF2; CLCN5; TRPC6; COL4A4; EYA1; HNF1B; WT1; NBEA; m.3243A>G). Participants with a family history of CKD were more likely to have a positive result (odds ratio, 3.29; 95% confidence interval, 1.10 to 11.29). Thirteen percent of participants without a CKD family history had a positive result. In those who first presented in stage 5 CKD, WGS with broad analysis of a curated kidney disease gene panel was diagnostically more informative than kidney biopsy, with biopsy being inconclusive in 24 of the 25 participants. Conclusions: In this prospectively ascertained Australian cohort, we identified a genetic diagnosis in 25% of patients with kidney failure of unknown cause.

2 August 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MWMathew Wallis
Mathew Wallis
SBSimon D. Bodek
Simon D. Bodek
JMJacob Munro
Jacob Munro
HRHaloom Rafehi
Haloom Rafehi
MBMark F. Bennett
Mark F. Bennett
SBSamuel F. Berkovic
Samuel F. Berkovic
Background: Significant recent efforts have facilitated increased access to clinical genetics assessment and genomic sequencing for children with rare diseases in many centres, but there remains a service gap for adults. The Austin Health Adult Undiagnosed Disease Program (AHA-UDP) was designed to complement existing UDP programs that focus on paediatric rare diseases and address an area of unmet diagnostic need for adults with undiagnosed rare conditions in Victoria, Australia. It was conducted at a large Victorian hospital to demonstrate the benefits of bringing genomic techniques currently used predominantly in a research setting into hospital clinical practice, and identify the benefits of enrolling adults with undiagnosed rare diseases into a UDP program. The main objectives were to identify the causal mutation for a variety of diseases of individuals and families enrolled, and to discover novel disease genes. Methods: Unsolved patients in whom standard genomic diagnostic techniques such as targeted gene panel, exome-wide next generation sequencing, and/or chromosomal microarray, had already been performed were recruited. Genome sequencing and enhanced genomic analysis from the research setting were applied to aid novel gene discovery. Results: In total, 16/50 (32%) families/cases were solved. One or more candidate variants of uncertain significance were detected in 18/50 (36%) families. No candidate variants were identified in 16/50 (32%) families. Two novel disease genes (TOP3B, PRKACB) and two novel genotype–phenotype correlations (NARS, and KMT2C genes) were identified. Three out of eight patients with suspected mosaic tuberous sclerosis complex had their diagnosis confirmed which provided reproductive options for two patients. The utility of confirming diagnoses for patients with mosaic conditions (using high read depth sequencing and ddPCR) was not specifically envisaged at the onset of the project, but the flexibility to offer recruitment and analyses on an as-needed basis proved to be a strength of the AHA-UDP. Conclusion: AHA-UDP demonstrates the utility of a UDP approach applying genome sequencing approaches in diagnosing adults with rare diseases who have had uninformative conventional genetic analysis, informing clinical management, recurrence risk, and recommendations for relatives.

5 November 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
EMEllenore M. Martin
Ellenore M. Martin
MHMadeleine Harris
Madeleine Harris
TSTegan Stait
Tegan Stait
SCSarah Casauria
Sarah Casauria
EPEsther Pierini
Esther Pierini
JCJohn Christodoulou
John Christodoulou
Background: An estimated 1 in 12 individuals across the world have a rare disease. The Undiagnosed Diseases Network International (UDNI) recommend Undiagnosed Disease Programs (UDPs) as the best approach to facilitate diagnosis and support for those affected. The Australian Undiagnosed Diseases Network (UDN-Aus) was the first National Australian UDP initiative funded by the Medical Research Future Fund’s Genomics Health Futures Mission (MRFF2007567). Aims: UDN-Aus brings together an unprecedented national collaborative network for rare disease, aiming to improve the rate of genomic diagnoses for those with undiagnosed rare genetic conditions, enabling precise, personalised care to individuals throughout Australia. Methods: The research program recruited Australians who were seen through a clinical genetics service and remained undiagnosed following clinically available genomic testing. This paper outlines the approach taken to establish a national research project at 12 clinical recruitment sites. The methods detail the funding, aims, governance, study design, population and participation process, health economic research and preliminary results, and recommendations for future sustainability and implementation. Results: The study was approved by the Royal Children’s Hospital Human Research Ethics Committee on 19 November 2021 (RCH79712), with relevant site-specific approvals at local recruitment sites. Key benefits and barriers in the establishment of UDN-Aus are outlined. Conclusion: The successful establishment of this program required several components, including meaningful and ongoing community and stakeholder engagement, strategic appointment of key operational staff, and a tailored approach to facilitate more equitable enrolment. It also highlighted several crucial areas for consideration to ensure future sustainable implementation of a national UDP. These include continued investment in Australia’s national genomic data transfer policy and infrastructure, and research ethics and governance procedures imperative for the sustainable delivery of genomic research for rare disease.

17 August 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
KJKushani Jayasinghe
Kushani Jayasinghe
RTRigan Tytherleigh
Rigan Tytherleigh
SBStephanie Best
Stephanie Best
SBSimon Bodek
Simon Bodek
PBPaula Bussa
Paula Bussa
CQCatherine Quinlan
Catherine Quinlan
Key Points: We evaluated a hub and spoke mainstreaming model to enable nephrologists to order genomic tests independently in their clinic across the state of Victoria. Over 1000 tests were ordered, with the diagnostic yield remaining similar regardless of ordered by local nephrologists or tertiary genomics services. A mainstreaming model proved feasible, scalable, and clinically effective, offering a practical framework for integrating genomics to routine kidney care. Background: Genomic testing has substantial diagnostic and clinical value in nephrology, yet integrating testing into routine care requires service-level changes to ensure timely and equitable access. Methods: We conducted an observational cohort study at four tertiary centers, with a pragmatic, quasi-experimental design to evaluate evidence-informed, service-level interventions to make genomic testing more accessible and routinely embedded within nephrology practice. We implemented a hub and spoke model which provided nephrologists with training, practical resources, and regular case-based discussions, to support test ordering and interpretation within their own clinics. Laboratory audits (June 2021–July 2024) evaluated how public reimbursement and implementation interventions influenced testing patterns. Three periods were compared: prefunding, postfunding, and postintervention. Results: Across the study period, 1028 genomic tests were ordered (63% adults, 37% children; median age 32 years). Results were available for 1014 tests, with an overall diagnostic yield of 34%, which remained stable across all time points. The diagnostic yield was similar regardless of whether testing occurred at tertiary genomics services (249 of 772, 32%) or via local nephrologists (92 of 242, 38%). The number of unique providers ordering tests was higher (T1: 37, T2: 69, T3: 87). The proportion of testing in mainstream nephrology settings rose from 23% to 74%, while absolute testing numbers in multidisciplinary clinics remained consistent over the study period. Conclusion: Mainstreaming genomic testing in nephrology was feasible, scalable, and clinically effective. This model was associated with better access without compromising diagnostic yield and provides a practical framework for integrating genomic medicine into routine kidney care.

22 September 2023 in Research Square
Verified
Preprint
Open access
PDF file
MWMathew Wallis
Mathew Wallis
SBSimon Bodek
Simon Bodek
JMJacob Munro
Jacob Munro
HRHaloom Rafehi
Haloom Rafehi
MBMark F Bennett
Mark F Bennett
SBSamuel Berkovic
Samuel Berkovic
Background Significant recent efforts have facilitated increased access to clinical genetics assessment and genomic sequencing for children with rare diseases in many centres, but there remains a service gap for adults. The Austin Health Adult Undiagnosed Disease Program (AHA-UDP) was designed to complement existing UDP programs that focus on paediatric rare diseases and address an area of unmet diagnostic need for adults with undiagnosed rare conditions in Victoria, Australia. It was conducted at a large Victorian hospital to demonstrate the benefits of bringing genomic techniques currently used predominantly in a research setting into hospital clinical practice, and identify the benefits of enrolling adults with undiagnosed rare diseases into a UDP program. The main objectives were to identify the causal mutation for a variety of diseases of individuals and families enrolled, and to discover novel disease genes. Methods Unsolved patients in whom standard genomic diagnostic techniques such as targeted gene panel, exome-wide next generation sequencing (NGS), and/or chromosomal microarray, had already been performed were recruited. Genome sequencing (GS) and enhanced genomic analysis from the research setting were applied to aid novel gene discovery. Results In total, 16/50 (32%) families/cases were solved. One or more candidate variants of uncertain significance (VUS) were detected in 18/50 (36%) families. No candidate variants were identified in 16/50 (32%) families. Two novel disease genes (TOP3B, PRKACB) and two novel genotype-phenotype correlations (NARS, and KMT2C genes) were identified. Three out of eight patients with suspected mosaic tuberous sclerosis complex had their diagnosis confirmed which provided reproductive options for two patients. The utility of confirming diagnoses for patients with mosaic conditions (using high read depth sequencing and ddPCR) was not specifically envisaged at the onset of the project, but the flexibility to offer recruitment and analyses on an as-needed basis proved to be a strength of the AHA-UDP. Conclusion AHA-UDP demonstrates the utility of a UDP approach applying genome sequencing approaches in diagnosing adults with rare diseases who have had uninformative conventional genetic analysis, informing clinical management, recurrence risk, and recommendations for relatives.